Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Workday Inc (WDAY) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Workday (WDAY) trades at $188.77, up 0.28% today, with a bullish technical signal from moving averages and a consensus analyst price target of $203.19. The company has beaten earnings estimates for the last three quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45 billion in 2025, and recent news highlights AI product launches and strategic partnerships, though layoffs and a fraud investigation present headwinds.

WDAY offers growth potential driven by AI integration and expanding market presence, but faces risks from competitive pressures and execution challenges. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels. Investor sentiment is mixed amid operational adjustments and legal scrutiny.